A detailed history of Jpmorgan Chase & CO transactions in Procept Bio Robotics Corp stock. As of the latest transaction made, Jpmorgan Chase & CO holds 896,747 shares of PRCT stock, worth $87 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
896,747
Previous 73,189 1125.25%
Holding current value
$87 Million
Previous $3.62 Million 1414.57%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 12, 2024

BUY
$45.73 - $69.19 $37.7 Million - $57 Million
823,558 Added 1125.25%
896,747 $54.8 Million
Q1 2024

May 10, 2024

SELL
$40.38 - $50.75 $1.9 Million - $2.39 Million
-47,058 Reduced 39.13%
73,189 $3.62 Million
Q4 2023

Feb 12, 2024

SELL
$24.89 - $43.41 $64,913 - $113,213
-2,608 Reduced 2.12%
120,247 $5.04 Million
Q3 2023

Nov 14, 2023

BUY
$30.02 - $38.81 $26,897 - $34,773
896 Added 0.73%
122,855 $4.03 Million
Q2 2023

Aug 11, 2023

BUY
$26.7 - $37.02 $1.09 Million - $1.51 Million
40,843 Added 50.35%
121,959 $4.31 Million
Q1 2023

May 18, 2023

BUY
$26.64 - $39.74 $954,884 - $1.42 Million
35,844 Added 79.17%
81,116 $2.3 Million
Q1 2023

May 11, 2023

BUY
$26.64 - $39.74 $421,844 - $629,282
15,835 Added 53.79%
45,272 $1.29 Million
Q4 2022

Feb 13, 2023

BUY
$38.78 - $46.78 $124,561 - $150,257
3,212 Added 12.25%
29,437 $1.22 Million
Q3 2022

Nov 14, 2022

SELL
$30.9 - $50.65 $1.21 Million - $1.98 Million
-39,189 Reduced 59.91%
26,225 $1.09 Million
Q2 2022

Aug 11, 2022

BUY
$29.23 - $44.45 $1.76 Million - $2.67 Million
60,061 Added 1122.01%
65,414 $2.14 Million
Q1 2022

May 11, 2022

BUY
$16.89 - $35.74 $13,934 - $29,485
825 Added 18.22%
5,353 $188,000
Q4 2021

Feb 10, 2022

BUY
$24.6 - $46.29 $111,388 - $209,601
4,528 New
4,528 $113,000

Others Institutions Holding PRCT

About PROCEPT BioRobotics Corp


  • Ticker PRCT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 44,592,300
  • Market Cap $4.33B
  • Description
  • PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally-invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). The company also designs Aqu...
More about PRCT
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.